Pierre News Headlines

Dry Age-related Macular Degeneration Pipeline

(Albany, USA) DelveInsight’s ‘Dry Age-related Macular Degeneration Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Dry Age-related Macular Degeneration therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain.

For Dry Age-related Macular Degeneration emerging drugs, the Dry Age-related Macular Degeneration pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

To know more in detail about Dry Age-related Macular Degeneration pipeline insight, click here: Dry Age-related Macular Degeneration Pipeline

Dry Age-related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is a degenerative disease of the ocular-posterior segment’s center (the macula lutea) that causes slow degeneration of central vision and severe disability in affected individuals. Clinically, AMD is classified using various methods. One such approach is to categorize the disease as early-stage to late-stage (advanced AMD). Advanced AMD is divided into two types: nonexudative or atrophic AMD (dry AMD) and exudative or neovascular AMD (wet AMD).

Some of the Key Highlights from Dry Age-related Macular Degeneration Pipeline Report

·         Over 40+ Dry Age-related Macular Degeneration pipeline therapies are in various stages of growth, and their anticipated acceptance in the Dry Age-related Macular Degeneration market would significantly increase market revenue.

·         Leading Dry Age-related Macular Degeneration companies such as Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others are evaluating novel Dry Age-related Macular Degeneration treatment drugs candidate to improve the treatment landscape.

·         Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011,  4P-020, Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others.

·         Out of the emerging Dry Age-related Macular Degeneration therapies Eyecyte RPE (Eyestem), OLX301A (OliX Pharmaceuticals), and EYS809 (Eyevensys) are in the early stages of development for Dry AMD treatment. 

·         On January 13, 2022, ONL Therapeutics, announced that it had closed on its second tranche of the Company’s Series B financing. The total proceeds raised in Series B was USD 46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.

Request a sample and discover the recent advances in Dry Age-related Macular Degeneration therapies : https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight

Dry Age-related Macular Degeneration Pipeline Analysis: Drug Profile

ALK-001: Alkeus Pharmaceuticals

ALK-001 is a once-daily oral drug candidate in Phase III clinical trials for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates known as “dimers” are known to form rapidly in Stargardt due to a genetic defect or to accumulate with age in the case of dry AMD. These toxic dimers have been linked to the retinal degeneration seen in Stargardt and AMD. Dimers are formed when two molecules of vitamin A combine chemically. ALK-001 is a vitamin A derivative that has been chemically modified to prevent dimerization.

Zimura: Iveric bio

Zimura (avacincaptad pegol) is an investigational drug that targets and inhibits complement protein C5 cleavage and the formation of its downstream fragments, C5a and C5b. Zimura is thought to reduce or slow the chronic inflammation and cell death associated with the retinal ageing process by inhibiting the formation of membrane attack complex (MAC) and inflammasome activity, potentially avoiding or slowing the degeneration of retinal pigment epithelial cells.

Gain more knowledge on emerging Dry Age-related Macular Degeneration drugs: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight

DRY AMD Pipeline Therapies and Key Companies

·         Zimura: IVERIC bio

·         ALK-001: Alkeus Pharmaceuticals

·         GT005: Gyroscope Therapeutics

·         Risuteganib: Allegro Ophthalmics

·         GEM103: Gemini Therapeutics

·         CPCB-RPE1: Regenerative Patch Technologies

·         RPESC RPE 4W: Luxa Biotechnology

·         Eyecyte RPE: Eyestem

·         OLX301A: OliX Pharmaceuticals

·         EYS809: Eyevensys

Learn more about the FDA approved Dry Age-related Macular Degeneration therapies and Dry Age-related Macular Degeneration Clinical Trials 

Dry Age-related Macular Degeneration Pipeline Therapeutics Assessment

By Product Type

·         Monotherapy

·         Combination Therapy

By Stage

·         Discovery

·         Pre-Clinical

·         Phase I

·         Phase II

·         Phase III

·         Pre-registration

By Route of Administration

·         Oral

·         Parenteral

·         Intravenous

·         Subcutaneous

·         Topical

By Molecule Type

·         Monoclonal Antibodies

·         Peptides

·         Polymers

·         Small Molecule 

·         Gene Therapy

Got queries? Reach out for more information on Dry Age-related Macular Degeneration therapeutics: https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight

Scope of the Dry AMD Pipeline Report

Coverage: Global

Key Dry Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others

Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others

Table of Contents

1. Dry Age-related Macular Degeneration Pipeline Report Introduction

2. Dry Age-related Macular Degeneration Pipeline Report Executive Summary

3. Dry Age-related Macular Degeneration Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Dry Age-related Macular Degeneration Pipeline Therapeutics

6. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Pre-registration)

7. Dry Age-related Macular Degeneration Pipeline: Late Stage Products (Phase III)

8. Dry Age-related Macular Degeneration Pipeline: Mid Stage Products (Phase II)

9. Dry Age-related Macular Degeneration Pipeline: Early Stage Products (Phase I)

10. Dry Age-related Macular Degeneration Pipeline Therapeutic Assessment

11. Inactive Products in the Dry Age-related Macular Degeneration Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Dry AMD Companies

14. Key Products in the Dry Age-related Macular Degeneration Pipeline

15. Dry AMD Unmet Needs

16. Dry AMD Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which provides benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services